Could a cholera vaccine stop Kids' diarrhea?

NCT ID NCT07300462

First seen Jun 25, 2026 · Last updated Jul 10, 2026 · Updated 2 times

Summary

This large study tests whether an oral cholera vaccine can also protect children aged 2 to 14 from infectious diarrhea caused by other germs. 6,000 healthy kids will get either the vaccine or a placebo. The goal is to see if the vaccine lowers the number of diarrhea cases, building on earlier hints of broader protection.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
oral recombinant subunit B/bacterial cholera vaccine (enteric-coated capsules)
What this could lead to
If successful, this vaccine could help prevent common infectious diarrhea in children, reducing illness and antibiotic use.
What could go wrong
This is a large phase 4 trial, but the vaccine is being tested for a new use (non-cholera diarrhea). It may not work as well in real-world conditions, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIARRHEA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Anhui Provincial Center for Disease Control and Prevention

    Hefei, Anhui, China

  • Hubei Provincial Center for Disease Control and Prevention

    Wuhan, Hubei, China

  • Jiangsu Provincial Center for Disease Control and Prevention

    Nanjing, Jiangsu, China

  • National Institute for Communicable Disease Control and Prevention, China

    Beijing, Beijing Municipality, China

  • Shandong Provincial Center for Disease Control and Prevention

    Jinan, Shandong, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.